HCQS safe and effective treatment option for Rosacea, finds study

Written By :  Dr. Kamal Kant Kohli
Published On 2020-06-07 12:56 GMT   |   Update On 2020-06-11 05:53 GMT
Advertisement

A new study published in the Journal of the American Academy of Dermatology has revealed that Hydroxychloroquine is a safe and effective treatment option for Rosacea.

Rosacea is a chronic inflammatory skin disease characterized by facial erythema, papules, pustules, telangiectasia, and flushing.1 Oral doxycycline has been approved as a first-line systemic treatment for papulopustular rosacea, but it is not consistently effective and is occasionally associated with gastrointestinal, neurological, and infection-related adverse effects.

Advertisement

Hydroxychloroquine (HCQS) is currently used to treat patients with systemic autoimmune disease and is considered safe for use during pregnancy.

In this pilot study, the researchers investigated the efficacy and safety of HCQS for treating rosacea.

They carried out a double-blinded study and randomized patients with rosacea who received either oral hydroxychloroquine (HCQ) 200 mg twice daily (n=28) or doxycycline 100 mg once daily (n=30) for 8 weeks with no adjunct topical therapies.

At the end of treatment at 8 weeks, similar improvements were noted in the clinician's erythema assessment (CEA) success rates (89.28% vs 86.67%, P = .193), the investigator's global assessment (IGA) success of "clear" or "almost clear" rates (82.14% vs 93.33%, P = .555), changes in total rosacea-specific quality of life (RosaQoL) scores, and excellent improvement rate as measured by a CEA score of "clear" or "almost clear" (78.57% vs 70.00%, P = .052). Although all outcomes were similar between the two groups, noninferiority of HCQ to doxycycline was observed only in changes in RosaQoL scores.

The adverse events with HCQS were minor and included dry skin (14.3%), dry eye (7.1%) and dizziness (7.1%). At the 12-week follow-up, 4 and 3 patients reported recurrence in the HCQD and doxycycline groups, respectively.

The researchers concluded that HCQS may be an effective and safe option for rosacea. When compared with the commonly used doxycycline, advantages include safety during pregnancy and avoiding the concern for increased photosensitivity. Further investigation with a larger sample size and longer treatment duration is encouraged.

For further reference log on to:

Tags:    
Article Source : Journal of the American Academy of Dermatology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News